Emergent BioSolutions, Inc. (EBS)
Stock Price Chart
Key Info
| Market Cap | 7.06B |
| Revenue (ttm) | 1.26B |
| Net Income (ttm) | 170.30M |
| Shares Out | 52.92M |
| EPS (ttm) | 3.19 |
| PE Ratio | 41.82 |
| Forward PE | 20.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $133.42 |
| Previous Close | $134.94 |
| Change ($) | -1.52 |
| Change (%) | -1.13% |
| Day's Open | 134.90 |
| Day's Range | 131.60 - 136.02 |
| Day's Volume | 792,840 |
| 52-Week Range | 39.11 - 137.61 |
More Stats
| Market Cap | 7.06B |
| Enterprise Value | 7.58B |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 52.92M |
| Float | 44.87M |
| EPS (basic) | 3.27 |
| EPS (diluted) | 3.19 |
| FCF / Share | 3.69 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 2.39% |
| FCF Yield | 2.75% |
| Payout Ratio | n/a |
| Shares Short | 2.61M |
| Short Ratio | 2.14 |
| Short % of Float | 6.88% |
| Beta | 1.42 |
| PE Ratio | 41.82 |
| Forward PE | 20.00 |
| P/FCF Ratio | 36.40 |
| PS Ratio | 5.61 |
| PB Ratio | 5.77 |
| Revenue | 1.26B |
| Operating Income | 262.80M |
| Net Income | 170.30M |
| Free Cash Flow | 194.00M |
| Net Cash | -518.20M |
| Net Cash / Share | -9.79 |
| Gross Margin | 38.36% |
| Operating Margin | 20.87% |
| Profit Margin | 13.50% |
| FCF Margin | 15.41% |
| ROA | 7.83% |
| ROE | 15.57% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,106 | 782 | 561 | 489 | 489 | 404 | 313 | 282 | 273 | 286 |
| Revenue Growth | 41.36% | 39.49% | 14.75% | -0.11% | 20.98% | 29.33% | 10.95% | 3.11% | -4.47% | - |
| Gross Profit | 673 | 460 | 373 | 363 | 382 | 303 | 251 | 236 | 231 | 239 |
| Operating Income | 114 | 89.80 | 124 | 106 | 142 | 89.19 | 42.80 | 29.97 | 32.10 | 73.56 |
| Net Income | 54.50 | 62.70 | 82.60 | 51.80 | 62.87 | 36.74 | 31.14 | 23.52 | 23.02 | 51.70 |
| Shares Outstanding | 51.50 | 50.10 | 41.80 | 40.20 | 38.60 | 37.34 | 36.20 | 36.08 | 35.66 | 31.78 |
| Earnings Per Share | 1.04 | 1.22 | 1.71 | 1.13 | 1.41 | 0.88 | 0.85 | 0.65 | 0.64 | 1.59 |
| EPS Growth | -14.75% | -28.65% | 51.33% | -19.86% | 60.23% | 3.53% | 30.77% | 1.56% | -59.75% | - |
| Operating Cash Flow | 188 | 41.80 | 208 | 54.60 | 42.52 | 112 | 96.97 | 39.64 | 12.19 | 98.02 |
| Capital Expenditures | -86.90 | -72.10 | -54.80 | -76.20 | -44.81 | -30.67 | -42.02 | -53.85 | -54.03 | -22.10 |
| Free Cash Flow | 101 | -30.30 | 153 | -21.60 | -2.30 | 81.65 | 54.95 | -14.20 | -41.84 | 75.92 |
| Cash & Equivalents | 168 | 112 | 179 | 272 | 308 | 280 | 179 | 142 | 146 | 171 |
| Total Debt | 811 | 795 | 13.50 | 268 | 247 | 251 | 62.00 | 62.77 | 59.45 | 47.43 |
| Net Cash / Debt | -643 | -682 | 166 | 3.42 | 61.41 | 29.50 | 117 | 78.89 | 86.63 | 124 |
| Assets | 2,327 | 2,229 | 1,070 | 970 | 1,037 | 939 | 627 | 564 | 547 | 500 |
| Liabilities | 1,239 | 1,219 | 158 | 374 | 377 | 385 | 137 | 122 | 130 | 127 |
| Book Value | 1,089 | 1,011 | 912 | 596 | 660 | 553 | 490 | 441 | 414 | 369 |
Company Profile
Company Details
| Full Name | Emergent BioSolutions, Inc. |
| Country | United States |
| Employees | 1,834 |
| CEO | Robert G. Kramer |
Stock Information
| Ticker Symbol | EBS |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: EBS |
| IPO Date | November 15, 2006 |
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.